Browse the evidence

Modern incretin-based and multi-agonist peptide therapies (GLP-1, GIP/GLP-1, and triple agonists) induce double-digit percentage weight loss (15-25%) that approaches or exceeds outcomes historically associated with bariatric surgery.

If you have obesity, modern peptide therapies like tirzepatide or semaglutide can help you lose 15-25% of your body weight, which is significantly more than older drugs and approaches the results of surgery. These treatments work by targeting the hormones that control your hunger and metabolism. While they are injectable and can be expensive, they are increasingly considered first-line treatments, especially if you have other health risks like heart disease or diabetes. You should discuss these options with your doctor to see if they are appropriate for you.

Semaglutide 2.4 mg significantly reduces major adverse cardiovascular events (MACE) in individuals with overweight or obesity without diabetes, establishing pharmacological weight loss as cardiovascular risk-modifying therapy.

If you have overweight or obesity but no diabetes, semaglutide 2.4 mg can help reduce your risk of serious heart problems like heart attack and stroke. This benefit is independent of your blood sugar levels. It is an injectable medication taken once a week. You should talk to your doctor about whether this is right for you, especially if you have other cardiovascular risk factors.

Semaglutide (2.4 mg weekly) significantly improves MASH resolution and fibrosis in patients with F2-F3 fibrosis, with benefits extending to significant weight loss and metabolic improvements.

If you have moderate to advanced liver scarring (F2-F3) from metabolic issues, Semaglutide is a new once-weekly injection option. It significantly reduces liver inflammation and scarring, and also promotes weight loss and improves blood sugar and cholesterol. It is generally well-tolerated, though gastrointestinal side effects are common initially.

Semaglutide 2.4 mg/week significantly reduces major adverse cardiovascular events (MACE) in overweight or obese adults with preexisting cardiovascular disease but without diabetes.

If you are overweight or obese and have existing heart disease but no diabetes, ask your doctor about semaglutide 2.4 mg/week. It is the first obesity medication proven to lower the risk of heart attacks, strokes, and cardiovascular death. The treatment involves a weekly injection, starting at a low dose to minimize stomach issues, and has been shown to significantly improve cardiovascular outcomes over standard care alone.

Semaglutide 2.4 mg/week leads to significant weight loss and improvement in cardiovascular risk factors (blood pressure, lipids, inflammation) in overweight or obese adults without diabetes.

Semaglutide 2.4 mg/week helps overweight or obese individuals lose an average of 9.4% of their body weight over 104 weeks, compared to less than 1% with placebo. This weight loss is associated with improvements in blood pressure, cholesterol, and inflammation markers, contributing to better cardiovascular health.

Semaglutide 2.4 mg/week significantly reduces the incidence of new-onset type 2 diabetes and prediabetes in overweight or obese adults without diabetes.

For overweight or obese individuals without diabetes, semaglutide 2.4 mg/week reduces the risk of developing type 2 diabetes by 73% and prediabetes by 67% compared to placebo.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) significantly reduce major adverse cardiovascular events (MACE) and promote substantial weight loss in patients with or without diabetes, addressing core CMS components.

If you have obesity and cardiovascular risk factors, GLP-1 agonists like semaglutide or liraglutide are highly effective. They help you lose significant weight and reduce your risk of heart attacks and strokes. These are typically injected weekly or daily. Discuss with your doctor if you are a candidate, especially if you have obesity-related complications.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces substantial, sustained, and dose-dependent weight loss in adults with obesity, significantly outperforming placebo, semaglutide, and dulaglutide.

If you have obesity, Tirzepatide is a highly effective, once-weekly injection that helps you lose a significant amount of weight (up to 20% or more) by targeting the hormones that control hunger and fullness. It works better than other similar drugs and lifestyle changes alone. While it can cause temporary stomach issues like nausea, these usually get better over time. It is a long-term treatment for a chronic condition.

GLP-1 receptor agonists (Liraglutide 3.0 mg and Semaglutide 2.4 mg) produce superior weight loss and cardiovascular risk reduction compared to other pharmacotherapies, making them first-line pharmacological options for high-risk patients.

If lifestyle changes alone are insufficient, GLP-1 medications like Semaglutide or Liraglutide are the most effective pharmacological options, offering significant weight loss (up to 12+ kg) and cardiovascular benefits. They require weekly or daily injections and slow dose titration to manage side effects. Discuss cost and insurance coverage with your provider to determine if this is a viable long-term strategy.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce superior weight loss (>10% initial body weight) compared to other approved anti-obesity medications by acting centrally to increase satiety and reduce appetite.

If lifestyle changes alone haven't worked, GLP-1 agonists like semaglutide or tirzepatide are the most effective pharmacological options, capable of producing over 10% weight loss. These require weekly injections and a gradual dose titration to manage side effects like nausea.

Liraglutide and semaglutide are the only approved anti-obesity medications demonstrated to lower the risk of major cardiovascular events in patients with or without established cardiovascular disease.

For patients with obesity and existing heart disease or diabetes, Liraglutide (3mg daily) and Semaglutide (2.4mg weekly) are preferred because they reduce cardiovascular event risk, unlike other weight loss drugs.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss in adults and adolescents with obesity by delaying gastric emptying, suppressing appetite via central satiety pathways, and stimulating glucose-dependent insulin secretion.

GLP-1 and GIP medications (like semaglutide and tirzepatide) are highly effective for weight loss, achieving 15-20% body weight reduction in clinical trials. They work by slowing digestion and reducing hunger signals in the brain. Treatment involves weekly or daily injections with gradual dose increases to minimize stomach upset. These drugs are most effective when combined with a calorie-controlled diet and regular physical activity.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces HbA1c (up to 2.6%) and body weight (up to 12.9 kg) in Type 2 Diabetes patients, outperforming existing GLP-1 agonists and insulin.

Tirzepatide is a once-weekly injectable medication for Type 2 Diabetes that works by mimicking two gut hormones (GIP and GLP-1). It is highly effective at lowering blood sugar and promoting significant weight loss, often outperforming other common diabetes medications. Patients should expect a gradual dose increase to minimize stomach upset, and pharmacists play a key role in managing side effects and ensuring adherence.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces superior weight loss and glycemic control compared to placebo, semaglutide, and insulin in patients with type 2 diabetes and obesity.

Tirzepatide is a once-weekly injection for type 2 diabetes and obesity that works by mimicking two gut hormones (GLP-1 and GIP). It is more effective than single-hormone drugs and insulin for lowering blood sugar and losing weight. Common side effects like nausea usually improve over time. It is not for type 1 diabetes or those with a history of pancreatitis.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered subcutaneously once weekly, produces significantly greater weight loss than both placebo and semaglutide in patients with type 2 diabetes and obesity.

If you have obesity or Type 2 Diabetes, tirzepatide is a highly effective weekly injection that works by mimicking gut hormones to reduce appetite and improve metabolism. It causes more weight loss than existing options like semaglutide. While it can cause stomach issues like nausea, these are usually mild and can be managed by starting with a low dose and increasing it slowly over time under medical supervision.

GLP-1 receptor agonists (GLP-1 RAs) including semaglutide, tirzepatide, and liraglutide produce significant weight loss in adults with obesity, with efficacy increasing with higher doses and outperforming placebo.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, often producing 15-20% body weight reduction in clinical trials. They work by mimicking natural hormones to reduce appetite and slow digestion. While effective, they can cause gastrointestinal side effects like nausea, which are usually manageable and temporary. Consult a doctor to determine if this treatment is appropriate for your specific health profile.

Dual GIP/GLP-1 receptor agonism (tirzepatide) provides superior glycemic control and greater weight loss compared to single GLP-1 receptor agonists (semaglutide) and insulin analogues (degludec, glargine) in patients with Type 2 Diabetes.

For patients with Type 2 Diabetes seeking maximum glucose control and weight loss, dual GIP/GLP-1 agonists like tirzepatide offer superior results compared to standard GLP-1 drugs or insulin. The treatment involves a once-weekly injection with a gradual dose escalation to manage side effects. While gastrointestinal issues like nausea are common, they are generally mild and comparable to other injectable diabetes medications.

Semaglutide (2.4 mg weekly) combined with intensive behavioral therapy produces significantly greater weight loss (16.0%) and cardiometabolic improvements compared to behavioral therapy alone (5.7%).

If you have obesity or overweight with related health issues, combining a weekly semaglutide injection (titrated to 2.4 mg) with intensive lifestyle changes (diet, exercise, counseling) can lead to substantial weight loss (around 16%) and better heart health markers compared to lifestyle changes alone. Be aware that stopping the drug may lead to weight regain, so it is intended for long-term management.

Tirzepatide (5-15 mg weekly) results in significant mean weight loss (15.0-20.9%) and improvements in waist circumference, blood pressure, and lipid levels compared to placebo.

Tirzepatide, taken as a weekly injection at doses of 5, 10, or 15 mg, can lead to 15-21% weight loss over 72 weeks, along with improvements in blood pressure and lipids, compared to placebo.

Long-term use of GLP-1 receptor agonists (GLP-1 RAs) provides durable cardiovascular and metabolic protection without significant long-term adverse events, whereas discontinuation leads to rapid weight regain and reversal of cardioprotective benefits.

Treat obesity as a chronic condition requiring long-term management with GLP-1 RAs. Do not stop the medication once you reach your goal weight, as you will likely regain the weight and lose cardiovascular benefits. Expect gastrointestinal side effects early on, but know they usually improve after a few months. Work with your doctor to manage costs and side effects to maintain adherence.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) administered weekly via subcutaneous injection significantly reduces HbA1c and body weight in adults with type 2 diabetes compared to placebo, semaglutide, and insulin.

If you have type 2 diabetes, a once-weekly injection called tirzepatide can significantly lower your blood sugar and help you lose weight, often more effectively than insulin or other common diabetes medications. While you might experience some stomach upset initially, it usually gets better, and the benefits for your heart and liver are also promising.

Semaglutide (2.4mg weekly) leads to significant weight loss in adults with obesity or overweight, and maintaining treatment prevents weight regain.

For obesity, a once-weekly injection of semaglutide (2.4mg) can help you lose a significant amount of weight (15-20%). However, if you stop taking it, you will likely regain most of the weight, so it is intended for long-term use.

Long-acting GLP-1 receptor agonists (specifically Semaglutide 2.4 mg) and dual GIP/GLP-1 co-agonists (specifically Tirzepatide) produce clinically significant weight loss (12-18% average) in adults with obesity, significantly outperforming previous pharmacotherapies and rivaling bariatric surgery.

If you have obesity, older weight-loss drugs often fail to produce lasting results. Newer injectable medications like Semaglutide (Wegovy) and Tirzepatide (Mounjaro) work by mimicking gut hormones to reduce appetite and improve metabolism. In clinical trials, these drugs helped patients lose 12-18% of their body weight on average, with many losing over 20%. This level of weight loss is comparable to bariatric surgery. However, these are prescription medications with potential side effects like nausea, and they require weekly administration. Consult a doctor to see if you are a candidate.

GLP-1 receptor agonists (specifically semaglutide and tirzepatide) offer superior glycemic control and significant weight loss compared to other antidiabetic drugs, with tirzepatide showing potential for diabetes remission.

For type 2 diabetes, especially if you are overweight, GLP-1 agonists like semaglutide and tirzepatide are highly effective. Tirzepatide, in particular, has shown the ability to put diabetes into remission for many patients, along with significant weight loss.